Billionaire Investors Flock to These Ultra-High-Yield Dividend Stocks: Verizon, Pfizer, AGNC Investment

Investing on Wall Street presents a myriad of strategies to build wealth, yet one approach consistently stands out: buying and holding high-quality dividend stocks. Historical data backs this up, revealing that dividend-paying stocks have significantly outperformed their non-paying counterparts over the long haul. This isn't lost on the financial crème de la crème of Wall Street.

A recent regulatory disclosure gave us a peek into the trading activities of institutional investors managing over $100 million. These insiders needed to submit their Form 13F to the Securities and Exchange Commission, detailing their quarterly trades. Amid the buzz around AI and other hot stocks, it was intriguing to see billionaire investors zero in on ultra-high-yield dividend picks. By 'ultra-high-yield,' we're talking about stocks delivering at least four times the yield of the S&P 500’s 1.35%. Let's dive into three of these compelling choices.

Verizon Communications: 6.58% Yield

Telecom giant Verizon Communications (NYSE: VZ) caught the eye of several billionaire investors throughout the first quarter. Heavyweights like Ken Griffin (Citadel Advisors), Israel Englander (Millennium Management), and Steven Cohen (Point72 Asset Management) collectively snapped up millions of Verizon shares. Why?

Primarily, Verizon's appeal lies in its essential services. In an age where wireless access and broadband services are considered necessities, consistent revenue streams and low churn rates are almost guaranteed. The likelihood of immediate financial liability seems low, making Verizon’s high yields and attractive valuation metrics all the more appealing.

Pfizer: 5.99% Yield

Pfizer (NYSE: PFE) also found favor with top-tier investors this past quarter. Prominent figures like John Overdeck and David Siegel (Two Sigma Investments), Steven Cohen (Point72 Asset Management), Ken Griffin (Citadel Advisors), and Ken Fisher (Fisher Asset Management) all increased their stakes in this pharmaceutical giant.

The pharmaceutical titan has faced some stock price turbulence recently, primarily due to the roller-coaster sales of its COVID-19 treatments, Comirnaty and Paxlovid. However, a broader perspective reveals a robust growth story. Even when accounting for the dip in COVID-19-related revenues, Pfizer’s overall sales portfolio is more diversified and stronger than before.

Moreover, Pfizer's $43 billion acquisition of Seagen brought fresh excitement, particularly in the oncology space. While acquisition costs might weigh on short-term earnings, the long-term potential of a bolstered cancer drug pipeline provides substantial promise. Consistent dividends from a solid pharmaceutical firm trading at roughly ten times forward earnings makes for an enticing proposition.

AGNC Investment: 15.06% Yield

Last but not least, the mortgage real estate investment trust AGNC Investment (NASDAQ: AGNC) offers a dividend yield that turns heads—a whopping 15%. Despite the industry being sensitive to interest rate fluctuations and having faced numerous challenges, billionaires John Overdeck and David Siegel (Two Sigma Investments), Israel Englander (Millennium Management), Ken Griffin (Citadel Advisors), and Jeff Yass (Susquehanna International) saw opportunity here.

History suggests that patience with mortgage REITs can be rewarded. The yield curve, which hasn’t been favorable lately, is bound to normalize eventually, improving AGNC's net interest margins and book value. Furthermore, with the Federal Reserve stepping back from purchasing mortgage-backed securities, AGNC has the chance to buy higher-yielding assets to hold long-term.

AGNC's massive $63.3 billion investment portfolio, largely backed by federal government guarantees, offers an added layer of security. This backing allows AGNC to leverage its investments for higher returns, supporting its hefty dividend payouts.

In conclusion, these three high-yield dividend stocks are clear favorites among some of Wall Street's most successful investors, showing that even in uncertain times, opportunities abound for those who know where to look.